Here's why severe asthma market is growing

Over 40 companies are working on more than 50 therapies for severe asthma.

The severe asthma market is growing due to a rising number of cases, particularly in urban areas and advancements in treatment, according to DelveInsight's report.

New biologic drugs targeting IgE and cytokine modulators are improving treatment options, while personalised medicine is enhancing both effectiveness and patient adherence.

Government initiatives and increased awareness are also expanding access to care, and advances in inhaler technology are further boosting medication adherence.

Moreover, collaboration in research and development is also driving innovation in asthma treatments.

The report also highlights a strong pipeline, with over 40 companies working on more than 50 therapies for severe asthma. Leading companies in this space include Kinaset Therapeutics, Bio-Thera Solutions, GlaxoSmithKline, AstraZeneca, Teva, and Sanofi, amongst others. These companies are developing new drugs to improve treatment outcomes.

Promising therapies in clinical trials include KN-002, BAT2606, CM326, Masitinib, GSK3511294, FB 704A, and others.

Severe asthma, which is characterized by persistent symptoms that don't respond well to standard treatment, can significantly impact quality of life and often leads to frequent hospitalizations. The growing pipeline of treatments offers hope for better management of the condition in the future.